A recently conducted meta-analysis of eight studies (214 patients in total) of patients receiving SGLT-2 inhibitors for type 2 diabetes mellitus and NAFLD (43) concluded that despite the low-to-moderate quality of evidence from the available pilot and observational studies, SGLT-2 inhibitors appear to improve transaminase levels, fatty liver, and fibrosis, along with providing additional metabolic effects, with the most common adverse effects being genitourinary tract infections. Here, SLC5A2 is linked to fatty liver disease.